vs
Esperion Therapeutics, Inc.（ESPR）与PREFORMED LINE PRODUCTS CO（PLPC）财务数据对比。点击上方公司名可切换其他公司
PREFORMED LINE PRODUCTS CO的季度营收约是Esperion Therapeutics, Inc.的1.0倍（$173.1M vs $168.4M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs 3.6%），过去两年PREFORMED LINE PRODUCTS CO的营收复合增速更高（10.8% vs 10.6%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
预成型线路产品公司（PLPC）研发、生产和销售适用于输配电、通信及可再生能源基建领域的工程硬件组件，服务全球多地的公用事业、网络运营商及工业客户，提供可提升网络可靠性与运营效率的解决方案。
ESPR vs PLPC — 直观对比
营收规模更大
PLPC
是对方的1.0倍
$168.4M
营收增速更快
ESPR
高出140.1%
3.6%
两年增速更快
PLPC
近两年复合增速
10.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $173.1M |
| 净利润 | — | $8.4M |
| 毛利率 | — | 29.8% |
| 营业利润率 | 50.6% | 6.8% |
| 净利率 | — | 4.9% |
| 营收同比 | 143.7% | 3.6% |
| 净利润同比 | — | -19.3% |
| 每股收益（稀释后） | $0.32 | $1.72 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRPLPC
| Q4 25 | $168.4M | $173.1M | ||
| Q3 25 | $87.3M | $178.1M | ||
| Q2 25 | $82.4M | $169.6M | ||
| Q1 25 | $65.0M | $148.5M | ||
| Q4 24 | $69.1M | $167.1M | ||
| Q3 24 | $51.6M | $147.0M | ||
| Q2 24 | $73.8M | $138.7M | ||
| Q1 24 | $137.7M | $140.9M |
净利润ESPRPLPC
| Q4 25 | — | $8.4M | ||
| Q3 25 | $-31.3M | $2.6M | ||
| Q2 25 | $-12.7M | $12.7M | ||
| Q1 25 | $-40.5M | $11.5M | ||
| Q4 24 | — | $10.5M | ||
| Q3 24 | $-29.5M | $7.7M | ||
| Q2 24 | $-61.9M | $9.4M | ||
| Q1 24 | $61.0M | $9.6M |
毛利率ESPRPLPC
| Q4 25 | — | 29.8% | ||
| Q3 25 | — | 29.7% | ||
| Q2 25 | — | 32.7% | ||
| Q1 25 | — | 32.8% | ||
| Q4 24 | — | 33.3% | ||
| Q3 24 | — | 31.1% | ||
| Q2 24 | — | 31.9% | ||
| Q1 24 | — | 31.3% |
营业利润率ESPRPLPC
| Q4 25 | 50.6% | 6.8% | ||
| Q3 25 | -11.4% | 7.4% | ||
| Q2 25 | 8.6% | 10.1% | ||
| Q1 25 | -34.0% | 8.8% | ||
| Q4 24 | -6.4% | 10.5% | ||
| Q3 24 | -31.0% | 7.1% | ||
| Q2 24 | 3.5% | 8.1% | ||
| Q1 24 | 52.5% | 8.2% |
净利率ESPRPLPC
| Q4 25 | — | 4.9% | ||
| Q3 25 | -35.9% | 1.5% | ||
| Q2 25 | -15.4% | 7.5% | ||
| Q1 25 | -62.2% | 7.8% | ||
| Q4 24 | — | 6.3% | ||
| Q3 24 | -57.2% | 5.2% | ||
| Q2 24 | -83.9% | 6.8% | ||
| Q1 24 | 44.3% | 6.8% |
每股收益（稀释后）ESPRPLPC
| Q4 25 | $0.32 | $1.72 | ||
| Q3 25 | $-0.16 | $0.53 | ||
| Q2 25 | $-0.06 | $2.56 | ||
| Q1 25 | $-0.21 | $2.33 | ||
| Q4 24 | $-0.14 | $2.13 | ||
| Q3 24 | $-0.15 | $1.54 | ||
| Q2 24 | $-0.33 | $1.89 | ||
| Q1 24 | $0.34 | $1.94 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | — |
| 总债务越低越好 | — | $38.3M |
| 股东权益账面价值 | $-302.0M | $475.5M |
| 总资产 | $465.9M | $653.6M |
| 负债/权益比越低杠杆越低 | — | 0.08× |
8季度趋势，按日历期对齐
现金及短期投资ESPRPLPC
| Q4 25 | $167.9M | — | ||
| Q3 25 | $92.4M | — | ||
| Q2 25 | $86.1M | — | ||
| Q1 25 | $114.6M | — | ||
| Q4 24 | $144.8M | — | ||
| Q3 24 | $144.7M | — | ||
| Q2 24 | $189.3M | — | ||
| Q1 24 | $226.6M | — |
总债务ESPRPLPC
| Q4 25 | — | $38.3M | ||
| Q3 25 | — | $36.0M | ||
| Q2 25 | — | $31.8M | ||
| Q1 25 | — | $29.1M | ||
| Q4 24 | — | $20.8M | ||
| Q3 24 | — | $27.2M | ||
| Q2 24 | — | $31.6M | ||
| Q1 24 | — | $55.0M |
股东权益ESPRPLPC
| Q4 25 | $-302.0M | $475.5M | ||
| Q3 25 | $-451.4M | $466.3M | ||
| Q2 25 | $-433.5M | $460.7M | ||
| Q1 25 | $-426.2M | $435.8M | ||
| Q4 24 | $-388.7M | $422.3M | ||
| Q3 24 | $-370.2M | $429.0M | ||
| Q2 24 | $-344.2M | $416.2M | ||
| Q1 24 | $-294.3M | $413.4M |
总资产ESPRPLPC
| Q4 25 | $465.9M | $653.6M | ||
| Q3 25 | $364.0M | $644.6M | ||
| Q2 25 | $347.1M | $631.5M | ||
| Q1 25 | $324.0M | $592.5M | ||
| Q4 24 | $343.8M | $573.9M | ||
| Q3 24 | $314.1M | $592.0M | ||
| Q2 24 | $352.3M | $572.6M | ||
| Q1 24 | $373.1M | $586.1M |
负债/权益比ESPRPLPC
| Q4 25 | — | 0.08× | ||
| Q3 25 | — | 0.08× | ||
| Q2 25 | — | 0.07× | ||
| Q1 25 | — | 0.07× | ||
| Q4 24 | — | 0.05× | ||
| Q3 24 | — | 0.06× | ||
| Q2 24 | — | 0.08× | ||
| Q1 24 | — | 0.13× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | $21.9M |
| 自由现金流经营现金流 - 资本支出 | — | $11.8M |
| 自由现金流率自由现金流/营收 | — | 6.8% |
| 资本支出强度资本支出/营收 | 0.0% | 5.9% |
| 现金转化率经营现金流/净利润 | — | 2.60× |
| 过去12个月自由现金流最近4个季度 | — | $33.3M |
8季度趋势，按日历期对齐
经营现金流ESPRPLPC
| Q4 25 | $45.2M | $21.9M | ||
| Q3 25 | $-4.3M | $18.9M | ||
| Q2 25 | $-31.4M | $26.9M | ||
| Q1 25 | $-22.6M | $5.7M | ||
| Q4 24 | $-35.0M | $24.1M | ||
| Q3 24 | $-35.3M | $9.4M | ||
| Q2 24 | $-7.2M | $28.3M | ||
| Q1 24 | $53.8M | $5.8M |
自由现金流ESPRPLPC
| Q4 25 | — | $11.8M | ||
| Q3 25 | — | $8.3M | ||
| Q2 25 | — | $18.6M | ||
| Q1 25 | — | $-5.3M | ||
| Q4 24 | — | $20.6M | ||
| Q3 24 | $-35.5M | $5.8M | ||
| Q2 24 | $-7.3M | $24.6M | ||
| Q1 24 | $53.8M | $1.8M |
自由现金流率ESPRPLPC
| Q4 25 | — | 6.8% | ||
| Q3 25 | — | 4.7% | ||
| Q2 25 | — | 10.9% | ||
| Q1 25 | — | -3.6% | ||
| Q4 24 | — | 12.3% | ||
| Q3 24 | -68.7% | 3.9% | ||
| Q2 24 | -9.9% | 17.7% | ||
| Q1 24 | 39.0% | 1.3% |
资本支出强度ESPRPLPC
| Q4 25 | 0.0% | 5.9% | ||
| Q3 25 | 0.0% | 6.0% | ||
| Q2 25 | 0.0% | 4.9% | ||
| Q1 25 | 0.0% | 7.4% | ||
| Q4 24 | 0.0% | 2.1% | ||
| Q3 24 | 0.3% | 2.4% | ||
| Q2 24 | 0.1% | 2.7% | ||
| Q1 24 | 0.1% | 2.8% |
现金转化率ESPRPLPC
| Q4 25 | — | 2.60× | ||
| Q3 25 | — | 7.21× | ||
| Q2 25 | — | 2.12× | ||
| Q1 25 | — | 0.49× | ||
| Q4 24 | — | 2.30× | ||
| Q3 24 | — | 1.22× | ||
| Q2 24 | — | 3.02× | ||
| Q1 24 | 0.88× | 0.60× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
PLPC
暂无分部数据
